Načítá se...
Gene Therapy for Adenosine Deaminase Deficiency: A Comprehensive Evaluation of Short- and Medium-Term Safety
Loss of adenosine deaminase activity leads to severe combined immunodeficiency (ADA-SCID); production and function of T, B, and natural killer (NK) cells are impaired. Gene therapy (GT) with an autologous CD34(+)-enriched cell fraction that contains CD34(+) cells transduced with a retroviral vector...
Uloženo v:
| Vydáno v: | Mol Ther |
|---|---|
| Hlavní autoři: | , , , , , , , , |
| Médium: | Artigo |
| Jazyk: | Inglês |
| Vydáno: |
American Society of Gene & Cell Therapy
2018
|
| Témata: | |
| On-line přístup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5910668/ https://ncbi.nlm.nih.gov/pubmed/29433935 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.ymthe.2017.12.022 |
| Tagy: |
Přidat tag
Žádné tagy, Buďte první, kdo otaguje tento záznam!
|